Φορτώνει......
Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H(1)-antihistamines. Omalizumab is a humanized monoclonal anti-IgE antibody that binds with free IgE antibodies and reduces the circulating levels of fre...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Indian Dermatol Online J |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Medknow Publications & Media Pvt Ltd
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4763587/ https://ncbi.nlm.nih.gov/pubmed/26955580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2229-5178.174314 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|